Silence Therapeutics beat earnings on August 10. The stock jumped 23% that day. Now the options market is repricing the trade.
The put/call ratio hit 0.49 on August 11. That is 2.5 standard deviations above the 20-day mean of 0.17. For most of the past month, the PCR sat below 0.12 — call buyers had near-total dominance. The sharp PCR move does not signal a bearish pivot. At 0.49 it remains well below the 52-week high of 1.36. It reflects a more balanced options book after a 32% weekly gain — hedging activity catching up with a stock that moved fast.
Short interest rose 16.8% to 1.84 million shares on August 11. That is the highest level since early July. The previous range held flat at 1.57 million shares for most of the month — the single-day jump stands out.
Short sellers are pressing into the post-earnings bounce. The borrow market is not signalling stress from their side. Availability sits at 367%, meaning roughly three shares remain available to borrow for every one already out on loan. Cost to borrow has climbed 31% over the past week to 0.90% — still in low territory by any historical measure.
Morgan Stanley raised its price target on SLN from $25 to $32 on August 11, maintaining its Overweight rating. The mean analyst target across all coverage stands at $35.60. With the stock closing at $14.72, consensus implies significant gap-to-target even after the recent run.
HC Wainwright holds a $75 target. Goldman Sachs maintains a Sell with a $3 target. The range of conviction across the street is unusually wide — a characteristic of early-stage siRNA biotechs where trial outcomes dominate the valuation.
The factor score for EPS surprise reads 93 — top decile. The 23% stock move on earnings day confirmed the market's reaction. The ORTEX short score sits at 48.6, essentially neutral and little changed over the past week.
The largest shareholder, Richard Griffiths, sold roughly $16.4 million in shares at $10.50–$10.76 in late June and early July — well below current levels. He still holds 9.68 million shares, or 20.5% of the company.
See the live data behind this article on ORTEX.
Open SLN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
